Genzyme rare-disease drug gets priority label

Share this article:

The FDA granted priority review status to Genzyme's experimental, all-oral Gaucher's disease treatment Cerdelga (eliglustat).

The FDA's priority label means the regulator will decide for or against the twice-a-day pill within six months.

The Sanofi subsidiary said in a statement that the 400-patient clinical trial supporting the filing is the largest ever conducted for Gaucher's disease.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

AstraZeneca takes on pediatricians

The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.

UK generic use soared in 2013

Generics made up almost 75% of prescriptions in the United Kingdom last year.

GSK refutes consumer spin-off rumor

The company refutes a Financial Times rumor that one was happening soonish.